Phase II Evaluation of Dalantercept in the Treatment of Persistent or Recurrent Epithelial Ovarian Cancer: an NRG Oncology/Gynecologic Oncology Group Study

OBJECTIVE: To determine the efficacy of dalantercept, a soluble ALK1 inhibitor receptor fusion protein, in patients with persistent or recurrent ovarian carcinoma and related malignancies METHODS: Eligibility criteria included measurable disease, 1-2 prior cytotoxic regimens and GOG performance stat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Gynecol Oncol
Egile Nagusiak: Burger, Robert A., Deng, Wei, Makker, Vicky, Collins, Yvonne, Gray, Heidi, Debernardo, Robert, Martin, Lainie P., Aghajanian, Carol
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6546175/
https://ncbi.nlm.nih.gov/pubmed/30041929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.06.017
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak